Patents Examined by Padmavathi Baskar
  • Patent number: 11285199
    Abstract: The present invention relates to a vaccine composition comprising a Staphylococcus aureus attenuated enterotoxin protein and cytotoxin protein, and more particularly to a Staphylococcus aureus enterotoxin protein, a Staphylococcus aureus cytotoxin protein, a vaccine composition for prevention of bovine mastitis, comprising the Staphylococcus aureus enterotoxin protein and Staphylococcus aureus cytotoxin protein and a method for preventing bovine mastitis comprising administering the vaccine composition to a bovine.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 29, 2022
    Assignees: Mississippi State University
    Inventors: Dong Chan Moon, Suk Kyung Lim, Keum Chan Jang, Suk Chan Jung, Hee Soo Lee, Bang Hun Hyun, Hyang Mi Nam, Heui Jin Kim, Keun Seok Seo
  • Patent number: 11275082
    Abstract: The present invention provides a method and a system for detecting the presence of an analyte in a sample. In particular, the present invention provides a system, such as a diagnostic kit, for detecting the presence of an analyte in a sample, comprising (a) a recombinant bacterium or spore expressing one or more recombinant proteins on the surface thereof, wherein the recombinant protein specifically binds to the analyte directly or through a binding agent that specifically binds to the recombinant protein and the analyte, and (b) a signal-producing substance that can be detected.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: March 15, 2022
    Inventor: Shao-Yi Hou
  • Patent number: 11275086
    Abstract: The present invention refers to the use of gene sequences or portions thereof characterized in that the same belong to the classes of in vitro and ex vivo induced, repressed or conserved genes in Mycobacterium tuberculosis currently infected human macrophages and to corresponding peptides or consensus peptides or proteins for the preparation of specific bio-markers for the diagnosis and prevention of active or latent disease.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: March 15, 2022
    Assignee: Cellestis Limited
    Inventors: Francesca Mariani, Massimo Amicosante, Vittorio Colizzi, Cesare Saltini
  • Patent number: 11273213
    Abstract: Provided herein are chimeric recombinant polypeptides (chimeritopes) for use in vaccines against Anaplasmosis, in assays for diagnosing Anaplasmosis and in assays for measuring antibody titers induced by vaccination. The chimeritopes comprise, for example, antigenic segments of three Anaplasma proteins (OmpA, AipA and Asp14) and a non-antigenic segment of a Borrelia Osp protein (e.g. OspC) that is 10 amino acids in length, proline rich and random coil in conformation. Compositions comprising the chimeritopes, optionally in combination with additional Anaplasma proteins of interest, are also provided, as are methods of using the compositions as vaccines and diagnostic tools.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: March 15, 2022
    Assignee: Virginia Commonwealth University
    Inventors: Richard T. Marconi, Jason A. Carlyon
  • Patent number: 11266731
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to immunogenic compositions and vaccines comprising detoxified pneumolysin adsorbed onto aluminium phosphate and an improved process for the adsorption of detoxified pneumolysin onto aluminium phosphate. It additionally relates to the use of the immunogenic compositions and vaccines in the treatment or prevention of Streptococcu pneumoniae infection.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: March 8, 2022
    Inventors: Laurence Danielle Ghenne, Dominique Ingrid Lemoine, Frédéric Mathot, Florence Emilie Jeanne Francoise Wauters
  • Patent number: 11260085
    Abstract: There is provided a salt-tolerant Lactobacillus having high foodstuff suitability, being easily produced, and having an immunostimulatory action. Salt-tolerant Lactobacillus having an immunostimulatory action with viability and activation potency of B cells.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: March 1, 2022
    Inventors: Toshihiko Kumazawa, Atsuhisa Nishimura, Noriyuki Asai, Takahiro Adachi
  • Patent number: 11261220
    Abstract: An isolated polypeptide includes the amino acid sequence EEAEKAKEAAEKALNEAFE or an amino acid sequence with a sequence identity of least 70%, 80%, or 90% identity to that sequence. The polypeptide is no longer than 200 or 170 amino acids. A nucleic acid encodes the polypeptide, a gene therapy vector includes the nucleic acid and genetically modified cells express the polypeptide. The polypeptide, the nucleic acid, the gene therapy vector and/or the cell can be used for the treatment of a disease associated with pathogenic long-lived plasma cells.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: March 1, 2022
    Inventors: Koji Tokoyoda, Akiko Takaya
  • Patent number: 11253581
    Abstract: The present disclosure relates to a composition for preventing and treating Mycoplasma synoviae infection, the composition comprising Tuf, NOX, MS53-0285 or a combination thereof as active ingredients. The composition of the present disclosure is effective in alleviating symptoms caused by Mycoplasma synoviae infection and can be used as an effective tool in preventing or treating poultry diseases.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: February 22, 2022
    Inventors: Jiunn-Horng Lin, Ho-Yuan Chou, Jyh-Perng Wang, Zeng-Weng Chen, Weng-Zeng Huang, Hsiu-Hui Wu, Hui-Jie Lin, Sheng-Xiang Huang
  • Patent number: 11246915
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: February 15, 2022
    Assignee: Applied Molecular Transport Inc.
    Inventors: Randall J. Mrsny, Tahir Mahmood
  • Patent number: 11243203
    Abstract: The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's GI tract, specifically the GI tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in GI tract samples, e.g. by nucleic acid analysis.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: February 8, 2022
    Inventors: Finn Terje Hegge, Christina Casen, Jorgen Valeur, Arne Roseth, Milada Cvancarova Smastuen
  • Patent number: 11241488
    Abstract: The application relates to methods for the diagnosis, treatment, and prevention of autoimmune and/or inflammatory disease such as systemic lupus erythematosus (SLE), lupus nephritis, IgA nephropathy, other types of glomerulonephritis.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: February 8, 2022
    Inventor: Gregg Silverman
  • Patent number: 11234934
    Abstract: A method comprises preparing initial agent molecules and applying the initial agent molecules to microbes for extracellular vesiculation. Microbial vesicles are generated which contain the initial agent molecules by the microbes. The packaged microbial vesicles are then administered to a host organism. By administering the initial agent molecules as a microbial vesicle package, binding proteins for the initial agent molecules may be co-administered, and cells may uptake numerous initial agent molecules concurrently.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: February 1, 2022
    Inventor: Sunny Leigh
  • Patent number: 11235022
    Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: February 1, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Ruchi Mathur, Christopher Chang
  • Patent number: 11235046
    Abstract: Disclosed are capsular polysaccharide (CPS)-protein immunogenic conjugates useful for providing protection against any condition or disease associated with Burkholderia pseudomallei or Burkholderia mallei, such as melioidosis or glanders, respectively. For example, a disclosed CPS-protein immunogenic conjugate includes purified 6-deoxyheptan capsular polysaccharide (CPS) from B. pseudomallei chemically activated and covalently linked to recombinant CRM 197 diphtheria toxin mutant (CRM197) to produce CPS-CRM197. Methods of inducing an immune response are disclosed. The methods include the use of a CPS-protein immunogenic conjugate, alone or in conjunction with other agents, such as Hcp1 and TssM, to prevent infection with B. pseudomallei or B. mallei. Also disclosed are methods for treating a subject having melioidosis or glanders.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 1, 2022
    Assignee: Nevada Research & Innovation Corporation
    Inventors: Paul J. Brett, Mary N. Burtnick
  • Patent number: 11230694
    Abstract: The present invention belongs to the field of the biotechnology, and relates to novel Streptococcusbacteria which are useful as antimicrobial agents, particularly against caries and periodontal disease. The invention relates to compositions and functional food comprising the novel bacteria. In particular, the present invention relates to a novel bacterial strain, deposited at the Colección Española de Cultivos Tipo, with accession number CECT 9174, which has proven to be useful in the prevention and treatment of caries and periodontal disease.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: January 25, 2022
    Inventors: Lucía Martínez Lamas, Maximiliano Álvarez Fernández, Pedro Diz Dios, Jacobo Limeres Posse
  • Patent number: 11224620
    Abstract: The invention provides compositions comprising one or more bacterial strains for treating or preventing visceral hypersensitivity.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: January 18, 2022
    Assignee: 4D PHARMA PLC
    Inventors: Annick Bernalier-Donadille, Laureen Crouzet, Chloe Habouzit
  • Patent number: 11224640
    Abstract: The present invention relates to a liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor. A liquid formulation containing botulinum toxin and stabilizing agent according to the present invention can be easily stored and distributed. It was proved a significant effect on the stabilization of botulinum toxin under suitable conditions according to the temperature and pH of the human body. Thus, it is expected that the pharmaceutical composition of the present invention will greatly contribute to the safe and convenient medical use of botulinum toxin.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: January 18, 2022
    Assignee: Hugel Inc.
    Inventors: Chee Gun Lee, Ji Hyun Oum
  • Patent number: 11213554
    Abstract: A method for the prevention or treatment of infections contracted by newborns of livestock mammals, which includes applying a composition that includes a mixture of bacterial strains to the perineum and/or the teat(s) of female livestock mammal that is going to give birth or has given birth to the newborn livestock mammals. Also, a kit for preventing digestive, respiratory or other infections in newborn livestock mammals, which includes at least one composition and at least one application element for applying the composition to the perineum and/or to the teats of the female livestock mammals.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: January 4, 2022
    Assignee: NOLIVADE
    Inventors: Michel Layus, Alexandre Brame
  • Patent number: 11191830
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: December 7, 2021
    Assignee: Wyeth LLC
    Inventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
  • Patent number: 11174308
    Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: November 16, 2021
    Inventors: Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu